Laboratory Reference Grade Compounds
Healing & Tissue Repair Peptides

BPC-157 Arginate Salt (10mg Acid-Stable Vial)

RUO In-VitroLyophilized Powder≥99% Reference Standard
Protocol SOP↓
₱3,270.00
Out of stock
InclusionAnalytical Lab Set
Net Content10MG
Volume Discounts:Up to 20% OFF
1
SOPReconstitution Telemetry (10MG)
Diluent:mL
Concentration10.00 mg/mLin 1.0mL BAC
Standard Dose250 mcg – 500 mcg Daily Oral / SubQSyringe: 5.0 units (0.05 mL)
Scale (1 Unit)100 mcgper 0.01 mL (U-100)
• Lyophilized vial onlyMonograph SOP →
BPC-157 Arginate Salt (10mg Acid-Stable Vial)10MG · Analytical Lab Set
₱3,270.00
1
Technical Specification & Protocol Dossier

Analytical Standards & Laboratory Handling

Verified laboratory protocols, reconstitution parameters, and handling guidelines.

P

Pharmacological Profile & Mechanism of Action

Research Monograph

What it is: BPC-157 Arginate is a stabilized salt form pairing the 15-amino-acid Body Protection Compound sequence with L-arginine, engineered to resist proteolytic gastric degradation.

How it works: Unlike standard BPC-157 acetate which degrades rapidly in human gastric juice (pH ~1–2), BPC-157 Arginate remains >90% intact after 5 hours in simulated gastric acid, allowing direct oral delivery while retaining full angiogenic and anti-inflammatory signaling.

Why researchers study it: Researched in oral models of inflammatory bowel disease (ulcerative colitis, Crohn's), mucosal ulcer healing, and systemic soft-tissue tendon repair.

Compound & Molecular Specifications

Certificate of Analysis Standards
Target CategoryTissue Repair & Healing
Intended ApplicationLaboratory & In-Vitro Research Only (RUO)
Physical StateLyophilized Solid Powder
CAS Registry Number137525-51-0 (Arg Salt)
PubChem CID9941957↗
Molecular Weight1593.7 g/mol
Purity Specification≥99.0% (HPLC-grade)
Net Content Options10MG
Inclusion PackagesVial Only, Vial + BAC Water, Analytical Lab Set
Peptide Sequence / FormulaGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val · L-Arginine
⚡ Pharmacodynamic Synergy·Verified Stacking Regimens

Frequently Stacked with BPC-157 (Pentadecapeptide)

Clinically verified combinations activating complementary physiological pathways without receptor competition.

Stacking Studio
Co-Administered Regimen

TB-500 (Thymosin Beta-4 Frag)

+98 Synergy
The Wolverine Stack: Dual Microvascular & Actin Remodeling Synergy

BPC-157 acts locally by accelerating microvascular angiogenesis via VEGFR2 and stabilizing granulation tissue, while TB-500 sequesters G-actin to drive rapid systemic cell migration and prevent fibrous adhesion/scar formation.

⏱In-vitro assay titration protocol•🛡Separate syringe
15% Off bundle
Compare
Co-Administered Regimen

GHK-Cu (Copper Tripeptide-1)

+93 Synergy
Microvascular & Extracellular Matrix Remodeling Synergy

BPC-157 rapidly generates fresh capillary networks (angiogenesis) to deliver oxygen and amino acids to damaged tissue, while GHK-Cu signals fibroblasts to synthesize new type I/III collagen and elastin while inhibiting TGF-beta scar formation.

⏱Administer in separate SubQ injections daily•🛡Separate syringe
15% Off bundle
Compare
Co-Administered Regimen

Tirzepatide

+91 Synergy
Incretin GI Tolerance & Mucosal Cytoprotection Stack

GLP-1 receptor agonists can cause transient delayed gastric emptying, nausea, and mucosal irritation. BPC-157 provides direct cytoprotective benefits across gastric epithelium, reducing gut discomfort while incretins drive metabolic weight loss.

⏱Tirzepatide: Weekly SubQ•🛡Separate syringe
15% Off bundle
Compare
Co-Administered Regimen

Semaglutide

+90 Synergy
GLP-1 Gut Barrier & Epithelial Recovery Stack

Semaglutide delays gastric motility to enhance satiety. BPC-157 upregulates tight junction proteins (Claudin, Zonula Occludens) and nitric oxide synthesis, minimizing digestive cramping and acid reflux in GLP-1 naive subjects.

⏱Semaglutide: Weekly SubQ•🛡Separate syringe
15% Off bundle
Compare